Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck transfers non-US Niaspan drug rights to Abbott
Abbott will take over marketing and distributing the product. The company acquired Kos Pharmaceuticals at the end of 2006. Merck entered into an agreement in 2002 with Kos
Abbott will take over marketing and distributing the product. The company acquired Kos Pharmaceuticals at the end of 2006. Merck entered into an agreement in 2002 with Kos
The condition is characterized by insufficient blood flow within the heart muscle, which gives rise to angina associated with coronary heart disease. Generx represents a new therapeutic class
Researchers found evidence that the drug could even contribute to swelling, heart failure and weight gain. The study examined pooled data from 18 past trials involving 8,000 patients.
MP-376 is a proprietary aerosolized formulation of the antibiotic levofloxacin that is being developed for the treatment of chronic lung infections due to pseudomonas aeruginosa in CF patients.
Ceftobiprole, an anti-MRSA antibiotic, was granted fast track designation by the FDA. The regulatory dossiers were submitted by Basilea’s co-development partner Johnson & Johnson in the US and
Under the terms of the agreement, Dompe will manufacture PRX321 at its facility in Italy for the upcoming pre-pivotal clinical trial and has committed to supply commercial batches
The company plans to report its annual 2007 results along with the new product business units. Crucell has appointed Mr Bjorn Sjostrand to head the vaccines business unit.
The company will now enter lead optimization as it continues to progress towards development. As a result of this identification, Pharmacopeia will receive a $500,000 milestone payment from
70 patients took part in the 52 week trial in Europe and Canada. Although interim analysis of patients in this trial at 36 weeks suggested a trend toward
The initial focus of the collaboration is to pursue treatments for orphan diseases of the mitochondria – the cellular energy center. Under the terms of the agreement, Penwest